Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (112)	9/22/1999 2:35:00 AM
From: scaram(o)uche	Respond to of 438

[ ignore, parking something ] Inventor(s): Vogelstein; Bert , Baltimore, MD Kinzler; Kenneth W. , Baltimore, MD Sherman; Michael I. , Glen Ridge, NJ Applicant(s): The John Hopkins University, Baltimore, MD PharmaGenics, Inc., Allendale, NJ Issued/Filed Dates: Nov. 8, 1994 / March 31, 1992 Application Number: US1992000860758 IPC Class: C12Q 001/68; Class: Current: 435/006; 435/320.1; 536/024.1; 536/024.31; Original: 435/006; 435/320.1; 536/024.1; 536/024.31; 424/002; Field of Search: 435/5,6,7.1,7.21,7.23,7.92,7.94,70.3,272,975,320.1 436/501,518,63,64,811,813 424/002 536/23.1,24.31,24.1 Government Info: This work was partially supported by the U.S. government under NIH grants CA06973, CA09243, CA35494, CA09071 and CA43460. The U.S. government retains certain rights in this invention. Priority Number(s): March 31, 1992 US1992000860758 Family Abstract: Specific sequences in the human genome are the sites of strong binding of wild-type p53 protein, but not mutant forms of the protein. These sequences are used diagnostically to detect cells in which the amount of wild-type p53 is diminished. The sequences can also be used to screen for agents which correct for loss of wild-type p53 to DNA in cancer cells. Attorney, Agent, or Firm: Banner, Birch, McKie & Beckett; Primary/Assistant Examiners: Nucker; Christine M.; Scheiner; Laurie Related Applications: Application Number ApplDate Patent Issued Title US1991000715182 1991-06-14 U.S. References: none First Claim: We claim: 1. A method of pre-screening agents for use in cancer therapy, comprising: measuring the amount of binding of a p53 protein encoded by a mutant gene found in cancer cells of a patient to a DNA molecule which conforms to the consensus binding site having more than one monomer of the double-stranded sequence RRRCWWGYYY; measuring the amount of binding of said p53 protein to said DNA molecule in the presence of a test substance; and comparing the amount of binding of the p53 protein in the presence of said test substance to the amount of binding of the p53 protein in the absence of said test substance, a test substance which increases the amount of binding being a candidate for use in cancer therapy.

To: scaram(o)uche who wrote (112)	9/22/1999 2:45:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 438

[ ignore, more parking ] US5700657: Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby Inventor(s): Beaudry; Gary A. , Montclair, NJ Bertelsen; Arthur H. , Ridgewood, NJ Sherman; Michael I. , GlenRidge, NJ Vogelstein; Bert , Baltimore, MD Applicant(s): Genzyme Corporation, Framingham, MA Issued/Filed Dates: Dec. 23, 1997 / Dec. 13, 1993 Application Number: US1993000166297 IPC Class: C12P 021/02; C12P 019/34; C12N 005/10; C12N 007/01; Class: Current: 435/069.1; 435/091.33; 435/235.1; 435/325; Original: 435/069.1; 435/091.33; 435/235.1; 435/325; Field of Search: 435/69.1,69.2,172.1,172.3,320.1,240.2,235.1,325,91.33,91.3,91.31,91.32 Priority Number(s): Dec. 13, 1993 US1993000166297 Abstract: Vectors and vector systems are embodied that include a gene encoding a tumor suppressor protein. In one embodiment, the vector includes a gene encoding a tumor suppressor protein and an inducible promoter controlling the gene encoding a tumor suppressor protein. The tumor suppressor protein may be p53 protein. In another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a nucleic acid sequence encoding an antisense sequence complementary to all or a portion of the gene encoding a tumor suppressor protein. In yet another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a gene which encodes a protein which binds to, and thereby inhibits, the tumor suppressor protein. Such vectors and vector systems enable cells transformed thereby to continue to proliferate such that adequate amounts of infectious viral particles, generated from viral vectors including a gene encoding a tumor suppressor protein, can be harvested for administration to patients. Attorney, Agent, or Firm: Olstein; E. M.; Lillie; R. J.; Primary/Assistant Examiners: Guzo; David; U.S. References: (No patents reference this one) Patent Issued Inventor(s) Title US4966847 10 /1990 McCormick et al. Recombinant DNA clones containing a broad host range gene from Bradyrhizobium japonicum US5087617 2 /1992 Smith Methods and compositions for treatment of cancer using oligonucleotides First Claim: What is claimed is: 1. A process for producing a retroviral vector particle in a producer cell comprising: producing a retroviral vector particle from a producer cell containing a retroviral vector including RNA or DNA encoding a tumor suppressor protein wherein expression of said tumor suppressor protein is controlled by an inducible promoter and said retroviral vector particle is produced under conditions under which the inducible promoter is not activated.